A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND STUDY TO EVALUATE THE TIME COURSE OF PHARMACODYNAMIC RESPONSE, SAFETY AND PHARMACOKINETICS OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2A

Registry ID
PS0016
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
UCB INC
Start date
2016-12-29
Last update
2016-11-09

Conditions

Related clinical trials

View on source registry